Loading
Immunotherapy and Immune Responses / CAR-T Cell Therapy Research / RNA Interference and Gene Delivery · Journal article
The Journal of Immunology · July 28, 2026
Encouraging direction, but not yet definitive.
In a mouse subcutaneous melanoma model, intratumoral mRNA-LNP vaccination with an irrelevant antigen (ovalbumin) induced tumor control without matching tumor neoantigens, and this effect was enhanced by concurrent systemic low-dose 4-1BB agonistic antibodies. The mechanism involved type I interferon induction and upregulation of costimulatory molecules, suggesting a bystander activation pathway rather than antigen-specific targeting.
Controlled preclinical in vivo study. C57BL/6 mice; specific group sizes and eligibility criteria not stated in abstract.. Intervention: Intratumoral mRNA-LNP vaccine encoding ovalbumin (mRNA-OVA), optionally combined with intraperitoneal 4-1BB agonistic antibodies (50 μg clone 3H3).. Compared with: mRNA-OVA alone versus mRNA-OVA plus 4-1BB antibodies; vehicle or untreated control not explicitly stated..
mRNA-OVA vaccination alone resulted in robust tumor control despite encoding an irrelevant antigen, with strongest OVA-specific CD8 T cell responders showing greatest tumor control Combined mRNA-OVA vaccination and 50 μg 4-1BB agonistic antibodies (clone 3H3) further enhanced anti-tumoral efficacy 4-1BB costimulatory regimen was well tolerated without elevated liver enzyme levels
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The finding that an off-the-shelf mRNA-LNP vaccine can drive tumor control without personalized neoantigen identification is conceptually important for immunotherapy development. However, this remains a single preclinical study; clinical translation and confirmation in human trials would be required before changing practice.
A controlled preclinical study demonstrating synergy between mRNA-LNP vaccination and 4-1BB costimulation in a single tumor model, with mechanistic insight but limited to mouse melanoma.
As stated by the source record.
Quoted from the source exactly as published.
The finding that an off-the-shelf mRNA-LNP vaccine can drive tumor control without personalized neoantigen identification is conceptually important for immunotherapy development. However, this remains a single preclinical study; clinical translation and confirmation in human trials would be required before changing practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Introduction Although mRNA—lipid nanoparticle (mRNA-LNP) vaccines are being explored as cancer immunotherapies, their clinical application is constrained by the need for personalized identification of tumor neoantigens and time-consuming vaccine design. Here, we investigated whether an off-the-shelf, antigen-mismatched mRNA-LNP vaccine could elicit bystander anti-tumoral effects without the need to express any tumor antigen. Methods C57BL/6 mice were challenged subcutaneously with 1x10^6 B16 melanoma cells, and five days later, they were immunized intratumorally with an mRNA-LNP encoding an irrelevant antigen, ovalbumin (mRNA-OVA), either alone or in combination with a tolerable dose of 4-1BB agonistic antibodies (50 μg of clone 3H3, administered intraperitoneally). Results Remarkably, mRNA-OVA vaccination alone resulted in robust tumor control despite the absence of any tumor antigen. Notably, mice mounting the strongest OVA-specific CD8 T cell responses exhibited the greatest tumor control, suggesting a role for bystander CD8 T cell activation in potentiating anti-tumoral activity. Importantly, the anti-tumoral efficacy of mRNA-LNP vaccination was further enhanced when combined with a low dose of costimulatory anti-4-1BB antibodies. This costimulatory anti-4-1BB regimen was well tolerated and did not result in elevated liver enzyme levels in mice. Mechanistically, mRNA vaccination induced potent type I interferon (IFN-I) responses, which increased the expression of costimulatory molecules, rendering tumors more responsive to costimulatory triggering. Conclusion Together, these findings demonstrate that mRNA-LNP vaccines promote anti-tumor immunity and can synergize with 4-1BB costimulation to enhance tumor control, providing a mechanistic rationale for combining mRNA vaccines with costimulatory immunotherapies. Funding Source n/a Topic Categories Tumor Immunology: Checkpoints, Prevention, and Treatment (TIPT)
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.